Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by gregoooon Jan 16, 2012 7:25pm

557 Views

Post# 19409750

Net Present Value (NPV)

As per the June 2011 corporate presentation (page 10) the NPV as per Petrotech and Ralph E Davis was 191.82 MM$, so if we have 600,000,000 shares thats about .30/share. IMO this was significantly increased today as this proves up Block 27. Now they need to prove up block 21. Go QEI Go

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload